Prevalence, Risk Factors and Clinical Characteristics in Patients with Genotype 6 Chronic Hepatitis C: A Single Institute Experience.
10.4166/kjg.2015.65.2.105
- Author:
Seung Kak SHIN
1
;
Soo Yong PARK
;
Young Kul JUNG
;
Eui Joo KIM
;
Heon Nam LEE
;
Jong Joon LEE
;
Oh Sang KWON
;
Duck Joo CHOI
;
Yun Soo KIM
;
Ju Hyun KIM
Author Information
1. Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea. jhkim@gilhospital.com
- Publication Type:Original Article
- Keywords:
Genotype 6;
Hepatitis C;
Prevalence;
Risk factors;
Treatment response
- MeSH:
Acupuncture Therapy;
Adult;
Aged;
Antiviral Agents/therapeutic use;
Blood Transfusion;
Drug Therapy, Combination;
Female;
Genotype;
Hepacivirus/*genetics/isolation & purification;
Hepatitis C, Chronic/*diagnosis/drug therapy/epidemiology;
Humans;
Interferon-alpha/therapeutic use;
Male;
Middle Aged;
Polyethylene Glycols/therapeutic use;
Prevalence;
RNA, Viral/genetics;
Recombinant Proteins/therapeutic use;
Republic of Korea;
Retrospective Studies;
Ribavirin/therapeutic use;
Risk Factors;
Tattooing
- From:The Korean Journal of Gastroenterology
2015;65(2):105-111
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Hepatitis C genotypes 1 and 2 are widely distributed globally. In contrast, genotype 6 is found mainly in Southeast Asia, while genotype 6 is rare in Korea. This study aims to investigate the prevalence, risk factors and clinical characteristics of patients with genotype 6 chronic hepatitis C. METHODS: We retrospectively identified 133 HCV-infected patients who underwent HCV genotype analysis between January 2012 and December 2012, and analyzed the prevalence, risk factors and clinical characteristics of patients diagnosed with genotype 6 chronic hepatitis C. RESULTS: Among 133 patients, 53 patients (39.8%) were infected with genotype 1, 62 patients (46.6%) with genotype 2, 2 patients (1.5%) with genotype 3, 14 patients (10.5%) with genotype 6, and 2 patients (1.5%) with mixed genotypes (genotype 1 and 6). The risk factors associated with genotype 6 were acupuncture (n=4, 28.6%), intravenous drug use (n=3, 21.4%), tattoo (n=2, 14.3%), and transfusion (n=2, 14.3%). Of the 14 patients with genotype 6, 6 patients were treated with pegylated interferon and ribavirin. Five patients had reached the end of treatment. All patients reaching end of treatment for genotype 6 showed early virological response and sustained virological response. CONCLUSIONS: The prevalence of genotype 6 is 10.5% and mixed infections of genotype 1 and 6 are 1.5% in patients with chronic hepatitis C. A major potential risk factor is intravenous drug use and the treatment response rate to pegylated interferon plus ribavirin is high in patients with genotype 6 chronic hepatitis C. Large scale multicenter studies are needed.
